{"nctId":"NCT00809965","briefTitle":"An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome","startDateStruct":{"date":"2008-11"},"conditions":["Acute Coronary Syndrome","Myocardial Infarction","Myocardial Ischemia","Unstable Angina"],"count":15526,"armGroups":[{"label":"Rivaroxaban 2.5 mg bid","type":"EXPERIMENTAL","interventionNames":["Drug: Rivaroxaban 2.5 mg","Drug: Standard of care"]},{"label":"Rivaroxaban 5 mg bid","type":"EXPERIMENTAL","interventionNames":["Drug: Rivaroxaban 5 mg","Drug: Standard of care"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Drug: Standard of care"]}],"interventions":[{"name":"Rivaroxaban 2.5 mg","otherNames":[]},{"name":"Rivaroxaban 5 mg","otherNames":[]},{"name":"Placebo","otherNames":[]},{"name":"Standard of care","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients must be currently receiving aspirin therapy alone or in combination with a thienopyridine per national or local dosing recommendation\n* Have been hospitalized for symptoms suggestive of acute coronary syndrome that lasted at least 10 minutes at rest and occurred 48 hours or less before going to the hospital\n\nExclusion Criteria:\n\n* Any condition that, in the opinion of the investigator, contraindicates anticoagulant therapy or would have an unacceptable risk of bleeding\n* Need for continued anticoagulant therapy\n* Significant renal impairment or known significant liver disease","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Percentage of Patients With the Composite Endpoint of Cardiovascular Death, Myocardial Infarction, or Stroke","description":"The percentage of patients with the first occurrence of the composite of death, myocardial infarction, or stroke. The statistical analysis was based on the time from randomization to the first occurrence of the event while on treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.4","spread":null},{"groupId":"OG001","value":"6.1","spread":null},{"groupId":"OG002","value":"6.1","spread":null}]}]}]},{"type":"SECONDARY","title":"The Percentage of Patients With the Composite of All Cause Death, Myocardial Infarction, or Stroke","description":"The percentage of patients with the first occurrence of the composite endpoint. The statistical analysis was based on the time from randomization to the first occurrence of the event while on treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.5","spread":null},{"groupId":"OG001","value":"6.3","spread":null},{"groupId":"OG002","value":"6.3","spread":null}]}]}]},{"type":"SECONDARY","title":"The Percentage of Patients With the Composite of Cardiovascular Death, Myocardial Infarction, Ischemic Stroke, or TIMI Major Bleeding Event Not Associated With Coronary Artery Bypass Graft Surgery","description":"The percentage of patients with the first occurrence of the composite endpoint. The statistical analysis was based on the time from randomization to the first occurrence of the event while on treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.6","spread":null},{"groupId":"OG001","value":"7.1","spread":null},{"groupId":"OG002","value":"7.2","spread":null}]}]}]},{"type":"SECONDARY","title":"The Percentage of Patients With the Composite of Cardiovascular Death, Myocardial Infarction, Stroke, or Severe Recurrent Ischemia Requiring Revascularization","description":"The percentage of patients with the first occurrence of the composite endpoint. The statistical analysis was based on the time from randomization to the first occurrence of the event while on treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.4","spread":null},{"groupId":"OG001","value":"8.5","spread":null},{"groupId":"OG002","value":"8.2","spread":null}]}]}]},{"type":"SECONDARY","title":"The Percentage of Patients With the Composite of Cardiovascular Death, Myocardial Infarction, Stroke, or Severe Recurrent Ischemia Leading to Hospitalization","description":"The percentage of patients with the first occurrence of the composite endpoint. The statistical analysis was based on the time from randomization to the first occurrence of the event while on treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.7","spread":null},{"groupId":"OG001","value":"7.3","spread":null},{"groupId":"OG002","value":"7.6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1018,"n":5125},"commonTop":["Epistaxis"]}}}